Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Clinical and Molecular Hepatology · 2023
DOI: 10.3350/cmh.2022.0322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2023. Verfasst von Jeong-Ju Yoo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Liver Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Education, Science and Technology, Soonchunhyang University.
Abstract (Originalsprache)
Background/Aims: The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in use correspond to histologic criteria in determining the IT phase and indication for liver biopsy.
Methods
Patients in the serological IT phase determined by positive hepatitis B e antigen, hepatitis B virus (HBV) DNA ≥106 IU/mL, and normal or minimally elevated alanine aminotransferase (ALT) ≤60 IU/L, who underwent liver biopsy at three different hospitals were included. The distribution of the histologic IT phase, defined as fibrosis of stage 1 or less and inflammation of grade 1 or less, was compared with that of the serological IT phase. The risk factors for the incidence of liver-related events, such as hepatocellular carcinoma, liver cirrhosis, liver transplantation, and death, were also analyzed.
Results
Eighty-two (31.7%) out of 259 clinically suspected IT phase patients belonged to the histologic IT phase. Age over 35, high AST, and low albumin were useful for ruling out the histologic IT phase. Risk factors predicting liver-related events were age and significant fibrosis stage. There was no significant difference in the proportion of histologic IT phase and clinical prognosis between normal ALT and mildly elevated ALT groups. However, even in patients with normal ALT, age was an important factor in predicting the presence of the histologic IT phase.
Conclusions
A significant number of patients who belonged to the serological IT phase were not in the histologic IT phase. Patients over 35 years and those with high AST, low albumin, and low HBV DNA levels were more likely to experience poor long-term clinical outcomes. Therefore, additional histologic assessment should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
- Department of Internal Medicine, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea.
- Department of Biostatistics, Clinical Trial Center, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
- Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
- College of Medicine, Soonchunhyang University, Cheonan, Korea.
- Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Education, Science and Technology
- Soonchunhyang University
Zitieren
APA
Yoo, J. J., Park, S. Y., Moon, J. E., Lee, Y. R., Lee, H. A., Lee, J., Kim, Y. S., Seo, Y. S., & Kim, S. G. (2023). Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2022.0322
Vancouver
Yoo JJ, Park SY, Moon JE, Lee YR, Lee HA, Lee J, et al. Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase. Clinical and Molecular Hepatology. 2023. doi:10.3350/cmh.2022.0322
BibTeX
@article{Yoo2023,
author = {Yoo, Jeong-Ju and Park, Soo Young and Moon, Ji Eun and Lee, Yu Rim and Lee, Han Ah and Lee, Jieun and Kim, Young Seok and Seo, Yeon Seok and Kim, Sang Gyune},
title = {Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase},
journal = {Clinical and Molecular Hepatology},
year = {2023},
doi = {10.3350/cmh.2022.0322}
}
EUVIMED